Anti-GM130 Antibody, clone 2M19 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 2M19 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects GM130. It targets an epitope with 19 amino acids from the N-terminal region.

KLH-conjugated linear peptide corresponding to 19 amino acids from the N-terminal region of human GM130.

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected GM130 in HeLa cell lysate.

Tested applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected GM130 in U2OS cell lysate.

Affinity Binding Assay: A representative lot of this antibody bound GM130 with a KD of 1.2 x 10-8 in an affinity binding assay.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected GM130 in human breast cancer and human colon cancer tissue sections.

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected GM130 in HeLa, HUVEC, and A431 cells..

Flow Cytometry Analysis: 1 μg from a representative lot detected GM130 in one million HeLa cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-GM130, clone 2M19 ZooMAb^®, Cat. No. ZRB1513, is a recombinant Rabbit monoclonal antibody that specifically detects GM130 and is tested in Affinity Binding Assay, Flow Cytometry, Immunocytochemistry, Immunohistochemistry, and Western Blotting.

Golgin subfamily A member 2 (UniProt: Q08379; also known as 130 kDa cis-Golgi matrix protein, GM130, GM130 autoantigen, Golgin-95) is encoded by the GOLGA2 gene (Gene ID: 2801) in human. GM130 is a peripheral membrane component of the cis-Golgi stack that acts as a membrane skeleton to maintain the structure of the Golgi apparatus, and as a vesicle tether that facilitates vesicle fusion to the Golgi membrane. It is required for normal protein transport from the endoplasmic reticulum to the Golgi apparatus and the cell membrane. Together with p115/USO1 and STX5, it is involved in vesicle tethering and fusion at the cis-Golgi membrane to maintain the stacked and inter-connected structure of the Golgi apparatus. At the onset of mitosis, GM130 undergoes phosphorylation at serine 37 by CDK1, which inhibits its interaction with p115/USO1 and prevents its tethering of COPI vesicles. This leads to inhibition of transport through the Golgi apparatus during mitosis. Upon phosphorylation, it interacts with importin-a via the nuclear localization signal region (aa 26-49), leading to recruitment of importin-a to the Golgi membranes and liberate the spindle assembly factor TPX2 from importin-a. TPX2 then activates Aurora kinase and stimulates local microtubule nucleation. GM130 is a homodimeric protein that may also assemble into homohexamers. It can also form a parallel homotetramer with a flexible rod-like structure that can give rise to I- and Y-shaped conformations. Selective deletion of GM130 in neurons is reported to cause fragmentation and defective positioning of the Golgi apparatus, impaired secretory trafficking, and dendritic atrophy in Purkinje cells. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Guo, H., et al. (2021). J. Cell Sci. 134(4); jcs258356; Liu, C., et al. (2017). Proc. Natl. Acad. Sci. USA. 114(2); 346-351; Wei, JH., et al. (2015). Cell. 162(2); 287-299).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb^® formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.